This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Support & resources

AMS resources

Access our Antimicrobial Stewardship Programme Resource Pack

Access AMS resources

SMART Hub

Access real-time stock monitoring, helpful information and videos about our supply chain, plus a range of training resources.

Access SMART Hub

Disease awareness resources

Access disease awareness downloadable resources

Download resources

** This is an optional area where footnotes can live.

Videos and case studies:

Listen to experts in a series of short videos present data on β-lactam/β-lactamase inhibitors, share their clinical experience using ZAVICEFTA and its use though a patient case.
Also gain access to webinars and recorded sessions of previous meetings available to view on demand

Access case studies and videos

Access case studies and videos

Header

This text is for block level content. P tags can go in here too

Paediatric Dosing

Join us!

Follow the link to learn about out upcoming meetings and online webinars event - dates, location and agendas.

Register here

Abbreviations

cUTI, complicated urinary tract infection, cIAI, complicated intra-abdominal infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; MDR, multi-drug resistant; BL/BLI, β-lactam/β-lactamase inhibitors; AMR, Antimicrobial Resistance; AMS, Antimicrobial Stewardship 

Prescribing information
​​​​​​​Zavicefta® (ceftazidime and avibactam)

PP-ZVA-GBR-1547. May 2022
Ask Zavibot a Question

How to Prepare

Find instructions for the preparation and administration of ZAVICEFTA

Zavicefta Preparation

Access results of ZAVICEFTA Phase III clinical trials in adult patients with cUTI, cIAI or HAP/VAP

View Phase III trial

Learn more about the tolerability data of ZAVICEFTA from four Phase III clinical trials.

View tolerability profile

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?